Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Josefa Vila"'
Publikováno v:
Nefrología, Vol 36, Iss 3, Pp 310-312 (2016)
La enfermedad de Fabry es una enfermedad de depósito lisosomal de carácter hereditario, ligada al cromosoma X, causado por el déficit de la enzima alfa-galactosidasa A (alfa-GLA A), lo que conduce a la acumulación de glicoesfingolípidos, princip
Externí odkaz:
https://doaj.org/article/8d124dc41a3e484981b7195ba7db235e
Publikováno v:
Nefrología (English Edition), Vol 36, Iss 3, Pp 310-312 (2016)
Fabry disease is an inherited, X-linked lysosomal storage disorder caused by deficiency of the enzyme alpha galactosidase A (alpha-GLA A), which leads to glycosphingolipid accumulation, mainly globotriaosylceramide, in tissues. Disease prevalence and
Externí odkaz:
https://doaj.org/article/3a9e090960284e26b9061e59f30bb492
Autor:
Leonor Pou, Antonia Arbós, Teresa Quiles, Josefa Vila, Luis Piera, Joaquim Majo, Alfons Segarra
Publikováno v:
Nephrology Dialysis Transplantation. 17:655-662
Background. Cyclosporin has improved the outcome for steroid-resistant patients with focal glomerulosclerosis, but there is a proportion of patients that are either cyclosporin-resistant or suffer relapses, needing long-term therapy to sustain the re
Autor:
Josefa Vila, Jorge Bartolomé, Joan Fort, Alfons Segarra, Cristina Martinez-Eyarre, Lluis Piera, Fernando Marco, Joaquin Camps, Xavier Argelaguer, Pilar Ruiz, Ernesto Moliner, Antoni Pelegrí, Pilar Chacón, A. Olmos
Publikováno v:
Journal of the American Society of Nephrology. 12:1255-1263
This study investigated the relationship between the circulating levels of the endothelial cell glycoproteins plasminogen activator inhibitor type 1 (PAI-1), tissue plasminogen activator (TPA), and thrombomodulin (TM) and the major vascular risk fact
Autor:
Josep Quer, Silvia Sauleda, Luis Piera, Juan Ignacio Esteban, Joan Genescà, Josefa Vila, J. Córdoba, Rafael Esteban, Jaime Guardia
Publikováno v:
Journal of Hepatology. 22:272-277
The presence and significance of hepatitis C virus infection was evaluated in 241 renal transplant recipients from our hospital. Hepatitis C virus antibodies were tested by second-generation enzyme immunoassay, followed by second- and third-generatio